AstraZeneca PLC (AZN)

AZN on New York Consolidated

71.69USD
19 Dec 2014
Price Change (% chg)

$-0.42 (-0.58%)
Prev Close
$72.11
Open
$71.11
Day's High
$72.06
Day's Low
$70.80
Volume
1,487,903
Avg. Vol
2,063,221
52-wk High
$82.68
52-wk Low
$58.29

AZN

Chart for AZN

About

AstraZeneca PLC (AstraZeneca) is a global biopharmaceutical company. AstraZeneca discovers, develops and commercializes prescription medicines for six areas of healthcare: Cardiovascular, Gastrointestinal, Infection, Neuroscience, Oncology, and Respiratory and Inflammation. It has a range of medicines that includes treatments... (more)

Overall

Beta: 0.57
Market Cap (Mil.): $89,932.70
Shares Outstanding (Mil.): 1,262.89
Dividend: 0.90
Yield (%): 3.88

Financials

  AZN Industry Sector
P/E (TTM): 88.75 37.39 38.03
EPS (TTM): 0.81 -- --
ROI: 2.60 19.00 18.26
ROE: 4.71 19.79 19.16
Search Stocks

AstraZeneca's ovarian cancer drug gets U.S. approval

- AstraZeneca Plc's ovarian cancer drug has been granted an accelerated approval by the U.S. health regulator, a day after the treatment was approved by the European Commission.

1:38pm EST

UPDATE 1-AstraZeneca's ovarian cancer drug gets U.S. approval

Dec 19 - AstraZeneca Plc's ovarian cancer drug has been granted an accelerated approval by the U.S. health regulator, a day after the treatment was approved by the European Commission.

1:33pm EST

FDA grants accelerated approval to AstraZeneca's ovary cancer drug

Dec 19 - AstraZeneca Plc's ovarian cancer drug has been granted an accelerated approval by the U.S. health regulator, a day after it was approved by the European Commission.

12:32pm EST

AstraZeneca first-in-class ovarian cancer drug wins EU approval

LONDON - AstraZeneca's all-important cancer drug business received a fillip on Thursday as a new medicine against ovarian cancer was approved in Europe, making it the first of its kind to reach the market.

18 Dec 2014

AstraZeneca first-in-class ovarian cancer drug wins EU approval

LONDON, Dec 18 - AstraZeneca's all-important cancer drug business received a fillip on Thursday as a new medicine against ovarian cancer was approved in Europe, making it the first of its kind to reach the market.

18 Dec 2014

BRIEF-Astrazeneca's Lynparza gets EU approval

* Lynparza approved in European Union as first-in-class treatment for advanced BRCA-mutated ovarian cancer Source text for Eikon: Further company coverage:

18 Dec 2014

AstraZeneca, Nektar constipation drug wins European approval

LONDON - AstraZeneca's new drug for the treatment of opioid-induced constipation, which was developed with Nektar Therapeutics, has been approved in the European Union, the British company said on Tuesday.

09 Dec 2014

AstraZeneca, Nektar constipation drug wins European approval

LONDON, Dec 9 - AstraZeneca's new drug for the treatment of opioid-induced constipation, which was developed with Nektar Therapeutics, has been approved in the European Union, the British company said on Tuesday.

09 Dec 2014

BRIEF-Astrazeneca's Moventig treatment approved in the EU

* Moventig  approved in european union for opioid-induced constipation Source text for Eikon: Further company coverage:

09 Dec 2014

AstraZeneca, Ranbaxy prevail in Nexium antitrust trial

- A Massachusetts jury has found that an agreement between AstraZeneca Plc and Ranbaxy Laboratories Ltd to delay the launch of a generic version of AstraZeneca's heartburn drug Nexium was not anticompetitive.

08 Dec 2014

Competitors

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: GlobalData
$125.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks